Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The market size for next-generation adeno-associated virus (AAV) gene therapy delivery has experienced swift expansion recently. This market is projected to expand from $4.96 billion in 2025 to $5.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.5%. Historically, this expansion was driven by several factors, including heightened gene therapy research activities, a rising prevalence of rare genetic disorders, greater investment in biotechnology innovation, the proliferation of clinical trials for AAV-based therapies, and an increasing demand for precise therapeutic strategies.
The market size for next-generation adeno-associated virus (AAV) gene therapy delivery is set to experience rapid expansion over the coming years. It is projected to reach $11.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.1%. This growth during the forecast period is primarily driven by the increasing uptake of personalized gene therapies, the accelerated creation of advanced AAV vector engineering platforms, the rising commercialization of gene therapy products, expanding research efforts in precision medicine applications, and a growing demand for enhanced safety and efficacy in genetic treatments. Significant trends expected during this period include the wider implementation of engineered AAV capsid technologies for targeted gene delivery, the continued development of strategies to reduce immune responses in AAV therapies, a heightened need for durable and precise gene expression platforms, the broadening applications of next-generation AAV vectors in treating rare diseases, and an increasing focus on scalable manufacturing processes for sophisticated gene therapy vectors.
Get A Free Sample Report With In-Depth Market Insights:
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Growth Factors Behind Sustained Expansion
The growing uptake of targeted gene therapies is projected to fuel the expansion of the next-generation adeno-associated virus gene therapy delivery market in the future. Targeted gene therapies are defined as a treatment method that introduces genetic material into particular cells or tissues within the body, aiming to rectify or alter disease-causing genes, all while reducing impacts on healthy cells. This rising adoption stems from developments in gene delivery technologies, which enhance the accuracy, safety, and effectiveness of delivering therapeutic genes straight to designated cells or tissues. The widespread acceptance of targeted gene therapies creates a need for more accurate, efficient, and tissue-specific delivery methods, consequently speeding up advancements and improvements in next-generation adeno-associated virus (AAV) gene therapy delivery platforms. For example, data from January 2024, provided by the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, indicated that in the fourth quarter of 2023, the volume of gene therapies in Phase III increased by 10% from the previous quarter, marking the initial rise since the third quarter of 2022. Consequently, the growing utilization of targeted gene therapies is a key factor boosting the expansion of the next-generation adeno-associated virus gene therapy delivery market.
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Segment Trends And Revenue Contributors
The next-generation adeno-associated virus (aav) gene therapy delivery market covered in this report is segmented –
1) By Type: Recombinant Adeno Associated Virus, Engineered Capsid Adeno Associated Virus, Self Complementary Adeno Associated Virus
2) By Delivery Method: In Vivo Delivery, Ex Vivo Delivery, Systemic Delivery, Localized Delivery
3) By Route Of Administration: Intravenous, Intrathecal, Intramuscular, Intravitreal
4) By Application: Neuromuscular Disorders, Ophthalmologic Diseases, Cardiovascular Gene Therapy, Rare Metabolic Disorders
5) By End User: Hospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
Subsegments:
1) By Recombinant Adeno Associated Virus: Serotype Diversity Variants, Tissue Tropism Optimized Vectors, Promoter Engineered Constructs, Genome Modified Vector Designs
2) By Engineered Capsid Adeno Associated Virus: Directed Evolution Capsids, Rationally Designed Capsids, Chimeric Capsid Variants, Peptide Insert Capsid Systems
3) By Self Complementary Adeno Associated Virus: Double Stranded Genome Vectors, Rapid Expression Vectors, Low Dose Therapeutic Vectors, Tissue Targeted Expression Vectors
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Industry Trends Fueling Future Revenue Growth
Companies operating in the next-generation adeno-associated virus gene therapy delivery market are primarily focusing on developing innovative solutions, such as engineered capsids, to enhance transduction efficiency, decrease necessary dosing, and improve overall safety and therapeutic effectiveness. Engineered capsids refer to genetically modified protein shells of adeno-associated viruses (AAVs) specifically designed to optimize gene delivery through improved tissue targeting, increased transduction efficiency, and reduced immune recognition. For instance, in May 2026, Affinia Therapeutics, a US-based biotechnology company, presented fresh preclinical and translational data at a major gene and cell therapy conference, underscoring advancements in its AAV gene therapy platform. This update showcased developments in capsid engineering, manufacturing scalability, and clinical trial design, all aimed at boosting targeted gene delivery efficiency. Particular emphasis was placed on its lead candidate, AFTX-201, for its potential in treating BAG3-associated dilated cardiomyopathy through amplified cardiac-specific gene expression utilizing a proprietary AAV vector.
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the next-generation adeno-associated virus (aav) gene therapy delivery market are Pfizer Inc., Novartis AG, Bayer AG, Astellas Pharma Inc., Sarepta Therapeutics Inc., Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V., Ring Therapeutics, Dyno Therapeutics Inc., Généthon, Sangamo Therapeutics Inc.
View The Full Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report:
Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the next-generation adeno-associated virus (AAV) gene therapy delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.